Adenosine A2A Receptor Ligation Inhibits Osteoclast Formation
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Adenosine is generated in increased concentrations at sites of injury/hypoxia and mediates a variety of physiological and pharmacological effects via G protein-coupled receptors (A(1), A(2A), A(2B), and A(3)). Because all adenosine receptors are expressed on osteoclasts, we determined the role of A(2A) receptor in the regulation of osteoclast differentiation. Differentiation and bone resorption were studied as the macrophage colony-stimulating factor-1-receptor activator of NF-κB ligand formation of multinucleated tartrate-resistant acid phosphatase (TRAP)-positive cells from primary murine bone marrow-derived precursors. A(2A) receptor and osteoclast marker expression levels were studied by RT-PCR. Cytokine secretion was assayed by enzyme-linked immunosorbent assay. In vivo examination of A(2A) knockout (KO)/control bones was determined by TRAP staining, micro-computed tomography, and electron microscopy. The A(2A) receptor agonist, CGS21680, inhibited osteoclast differentiation and function (half maximal inhibitory concentration, 50 nmol/L), increased the percentage of immature osteoclast precursors, and decreased IL-1β and tumor necrosis factor-α secretion, an effect that was reversed by the A(2A) antagonist, ZM241385. Cathepsin K and osteopontin mRNA expression increased in control and ZM241385-pretreated osteoclasts, and this was blocked by CGS21680. Micro-computed tomography of A(2A)KO mouse femurs showed a significantly decreased bone volume/trabecular bone volume ratio, decreased trabecular number, and increased trabecular space. A(2A)KO femurs showed an increased TRAP-positive osteoclast. Electron microscopy in A(2A)KO femurs showed marked osteoclast membrane folding and increased bone resorption. Thus, adenosine, acting via the A(2A) receptor, inhibits macrophage colony-stimulating factor-1-receptor activator of NF-κB ligand-stimulated osteoclast differentiation and may regulate bone turnover under conditions in which adenosine levels are elevated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bone Resorption by Osteoclasts
Teitelbaum, S. L. (2000) · Science · doi:10.1126/science.289.5484.1504 · Cited by 3,962
Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems
Takayanagi, H. (2007) · Nature Reviews Immunology · doi:10.1038/nri2062 · Cited by 1,878 · cited 2×
“RANKL binds to its receptor, RANK, on the surface of OCPs, activating signaling through NF- B, c-Fos, phospholipase C , and nuclear factor of activated T cells c1 (NFATc1), to induce differentiation of OCPs into osteoclasts.(9) Adenosine, the metabolic product of adenine nucleotide dephosphorylation, is generated intr…”
BackgroundYoshida, H., Hayashi, S.-I., Kunisada, T., Ogawa, M., Nishikawa, S., Okamura, H., Sudo, T., Shultz, L. D., & Nishikawa, S.-I. (1990) · Nature · doi:10.1038/345442a0 · Cited by 1,789
RANK is essential for osteoclast and lymph node development.
Dougall, W. C., Glaccum, M., Charrier, K., Rohrbach, K., Brasel, K., De Smedt, T., Daro, E., Smith, J., Tometsko, M. E., Maliszewski, C. R., et al. (1999) · Genes & Development · doi:10.1101/gad.13.18.2412 · Cited by 1,478
Adenosine Receptors as Therapeutic Targets
Jacobson, K. A., & Gao, Z.-G. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1983 · Cited by 1,431 · cited 1×
“phospholipase C and calcium mobilization (A2B and A3), phosphatidylinositol 3-kinase (A3), and protein kinase C and mitogen-activated protein kinases (A1, A2A, and A3 receptors).(21) Future experiments will be directed at the dissection of adenosine receptor signaling in OCPs and the role of cAMP or other intermediate…”
BackgroundLi, J., Sarosi, I., Yan, X.-Q., Morony, S., Capparelli, C., Tan, H.-L., McCabe, S., Elliott, R., Scully, S., Van, G., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.4.1566 · Cited by 1,119
Wei, S., Wang, M. W.-H., Teitelbaum, S. L., & Ross, F. P. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m104957200 · Cited by 202
Action of RANKL and OPG for Osteoclastogenesis
Kobayashi, Y., Udagawa, N., & Takahashi, N. (2009) · Critical Reviews™ in Eukaryotic Gene Expression · doi:10.1615/critreveukargeneexpr.v19.i1.30 · Cited by 176
Cited by
Regulation of Inflammation by Adenosine
Haskó, G., & Cronstein, B. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00085 · Cited by 367
Self-citationAdenosine and adenosine receptors in the pathogenesis and treatment of rheumatic diseases
Cronstein, B. N., & Sitkovsky, M. (2017) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2016.178 · Cited by 258
Self-citationMediero, A., & Cronstein, B. N. (2013) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2013.02.001 · Cited by 133
Self-citationMediero, A., Wilder, T., Perez‐Aso, M., & Cronstein, B. N. (2015) · The FASEB Journal · doi:10.1096/fj.14-265066 · Cited by 103
Self-citationMediero, A., Perez‐Aso, M., & Cronstein, B. N. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12227 · Cited by 93
Self-citation
Metadata
- Authors
- Mediero, A., Kara, F. M., Wilder, T., & Cronstein, B. N.
- Venue
- The American Journal of Pathology
- Publisher
- Elsevier BV
- Published
- 2012-02
- Volume
- 180
- Issue
- 2
- Pages
- 775-786
- ISSN
- 0002-9440 (ISSN-L)
- OpenAlex
- W2155544411
- Cited by
- 103
- References
- 8
- FWCI
- 2.00
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Adenosine A2A Receptor Ligation Inhibits Osteoclast Formation. https://app.cochat.ai/papers/10.1016/j.ajpath.2011.10.017
- The paper
- Mediero, A., Kara, F. M., Wilder, T., & Cronstein, B. N. (2012). Adenosine A2A Receptor Ligation Inhibits Osteoclast Formation. The American Journal of Pathology. https://doi.org/10.1016/j.ajpath.2011.10.017
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.